Biohaven Pharmaceuticals, Inc
Please note: The information displayed on this page might be outdated.
Biohaven Pharmaceuticals, Inc:
Commercial-stage, focused on neurological & neuropsychiatric diseases; CGRP receptor antagonist, glutamate modulation, and MPO platforms. NURTEC® ODT approved 1Q20 acute treatment of migraine and 1Q21 preventive treatment of migraine; $136m 3Q21 revenues. Plan to complete enrollment of verdiperstat for the treatment of ALS in 4Q21, and report topline of troriluzole in Spinocerebellar Ataxia in 2H22.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Marketed, Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
215 Church Street
New Haven, CT 06510
United States
New Haven, CT 06510
United States
More info:
My account:
Company Participants at Solebury Trout 1x1 Management Access Event 2022
- Matthew Buten, CFO
- Vlad Coric, M.D., Chief Executive Officer
Top 10 Holders of Biohaven Pharmaceutical Holding Company Ltd.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Capital Research & Management Co. (World Investors) | 10.03 | 7,075,514 | 1,004.94 | Stakes | 4/29/22 |
| Capital Research & Management Co. (Global Investors) | 8.49 | 5,988,509 | 850.55 | Funds | 3/31/22 |
| 1919 Investment Counsel LLC | 4.32 | 3,047,926 | 432.90 | 13F | 3/31/22 |
| Janus Henderson Investors US LLC | 3.82 | 2,694,432 | 382.69 | 13F | 3/31/22 |
| Capital Research & Management Co. (International Investors) | 3.80 | 2,682,916 | 381.05 | 13F | 3/31/22 |
| Marshall Wace LLP | 3.40 | 2,401,284 | 341.05 | 13F | 3/31/22 |
| BlackRock Fund Advisors | 3.37 | 2,375,716 | 337.42 | 13F | 3/31/22 |
| Allspring Global Investments LLC | 3.22 | 2,273,680 | 322.93 | 13F | 3/31/22 |
| Oracle Investment Management, Inc. | 2.92 | 2,061,402 | 292.78 | 13F | 3/31/22 |
| State Street Corp. | 2.35 | 1,655,834 | 235.18 | 13F | 3/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.